The Cytogenefics Core has been approved as an established Shared Resource of DF/HCC since it's founding. Charies Lee has directed the facility since 2006, after serving as its Assistant Director for six years. Cytogenetic studies can provide insight into regions of the genome that are pathogenetic in various neoplasms leading to an understanding ofthe molecular pathways participating in the biology of cancer. An invaluable function of the Cytogenetics Core is access to consultation for experimental design and data interpretation with the Core Directors. Consultation provides the investigator with guidance and advice regarding the best approach for the goal(s) of a specific study. Services of the Core are primarily focused on human and mouse cytogenetics and include: 1) conventional karyotyping of fissue specimens and cell lines, 2) fluorescence in situ hybridization (FISH) for metaphase and interphase preparations, and 3) comparative genomic hybridization (CGH) on microarrays. Director: Charies Lee, PhD(MWH) Category: 1.15 (Cytogenetics) Management: Joint (Cancer Center and Institutional).

Public Health Relevance

The mission of the Cytogenetics Core is to provide state-of-the-art cytogenetics services to DF/HCC scientists to facilitate investigations of the pathogenesis and pathobiology of neoplasia. Cytogenetic studies may also be important in establishing a diagnosis for correlation with clinical outcome. Cytogenetics is a fundamental adjunct to a variety of investigations underway, including basic and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$182,287
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Francini, Edoardo; Gray, Kathryn P; Xie, Wanling et al. (2018) Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78:889-895
Hu, Yanhui; Vinayagam, Arunachalam; Nand, Ankita et al. (2018) Molecular Interaction Search Tool (MIST): an integrated resource for mining gene and protein interaction data. Nucleic Acids Res 46:D567-D574
Mohr, Stephanie E; Rudd, Kirstin; Hu, Yanhui et al. (2018) Zinc Detoxification: A Functional Genomics and Transcriptomics Analysis in Drosophila melanogaster Cultured Cells. G3 (Bethesda) 8:631-641
Odiaka, Emeka; Lounsbury, David W; Jalloh, Mohamed et al. (2018) Effective Project Management of a Pan-African Cancer Research Network: Men of African Descent and Carcinoma of the Prostate (MADCaP). J Glob Oncol :1-12
Mills, Evanna L; Pierce, Kerry A; Jedrychowski, Mark P et al. (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature 560:102-106
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199

Showing the most recent 10 out of 411 publications